Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
6(66.7%)
Phase 2
3(33.3%)
9Total
Phase 1(6)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT05373914Phase 2Unknown

RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Role: lead

NCT04814498Phase 1Completed

Drug-Drug Interaction (DDI) Study in Healthy Volunteers

Role: lead

NCT04939467Phase 1Completed

Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

Role: lead

NCT04334460Phase 2Completed

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects

Role: lead

NCT04814472Phase 1Completed

Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations

Role: lead

NCT04146805Phase 1Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects

Role: lead

NCT04244825Phase 2Withdrawn

Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF

Role: lead

NCT04001998Phase 1Withdrawn

Healthy Volunteer Study Comparing Tablet and Capsule Formulations

Role: lead

NCT03559166Phase 1Completed

First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis

Role: lead

All 9 trials loaded